SANTIAGO, Chile (AP) – A real study of millions of Chileans who received the CoronaVac vaccine developed in China found that it was 67% effective against symptoms and 80% effective against death from COVID-19, according to the South American Ministry of Health. Friday
Rafael Araos, an adviser to the ministry, said the study included 10.5 million people, including 2.5 million who received two doses of the vaccine և 1.5 million who received a single dose between February 2 and April 1. :
It counted cases that started 14 days after the second dose of the vaccine, which was given in Chile 28 days after the first.
The vaccine is widely used around the world, though not in the United States or Europe.
Araos said it reduced hospitalization by 85%, intensive care visits by 89% and mortality by 80%.
It is one of the most widely published studies to date on any of the vaccines used against the new coronavirus. Most previous studies have relied on clinical trials of thousands of people who have been vaccinated before general use to test efficacy and safety.
Chile has led the region with a vaccination campaign that has reached 40% of its 19 million population, 27% of whom have received both doses so far. It started mostly with older nurses, but has expanded to include key workers and, more recently, 48-year-olds.
It was contracted over three years for 60 million doses of the CoronaVac vaccine produced by Sinovac, as well as the vaccines produced by Pfizer. About 90% of the vaccines used in Chile so far are CoronaVac.
Authorities said Thursday that hospitalizations of people over the age of 70 in Chile have been reduced as part of a vaccination campaign for the elderly. But it has seen a “steady rise” in the hospitalization of 59 փոքր smaller people.
The country has reported 1.1 million new virus infections and about 25,000 deaths.